Compare BioNano Genomics Inc (BNGO) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Northrop Grumman Corporation — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Northrop Grumman Corporation trades at $530.73 (market cap $75.09B). The key difference: Northrop Grumman Corporation is far larger — about 5688.6× BioNano Genomics Inc's market cap, and Northrop Grumman Corporation pays a 1.78% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | NOC | |
|---|---|---|
Market Cap | $13.20M | $75.09B |
Sector | Health | Industrials |
52-Week High | $4.92 | $768.02 |
52-Week Low | $1.09 | $496.02 |
Enterprise Value | $15.81M | $89.31B |
Dividend Yield | — | 1.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Northrop Grumman (NOC) trades at $541.82, up 0.41% with neutral technical signals. The company shows strong fundamentals with consistent earnings beats, a 10.8% net income margin, and a $96 billion backlog supporting growth. Recent news highlights expansion in defense and aerospace sectors, driven by increased government spending and new contracts.
Outlook is positive with a consensus price target of $655, indicating 21% upside. Risks include political budget shifts and execution challenges. Analyst sentiment is bullish (57% buy ratings), but investors should monitor Q2 2026 earnings due July 21 for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
